摘要
目的系统评价带状疱疹(herpes zoster,HZ)疫苗接种药物经济学研究,为相关研究及HZ的预防提供参考。方法以“带状疱疹”、“带状疱疹疫苗”、“药物经济学”、“经济学评价”、“成本–效果分析”及“herpes zoster”、“herpes zoster vaccines”、“pharmacoeconomics”、“cost-effectiveness analysis”等为主题词,检索4个中文数据库和4个英文数据库自建库至2023年1月有关带状疱疹疫苗接种的药物经济学研究文献,由2名研究者对检索出的文献进行2次独立筛选;参照世界卫生组织《免疫规划项目的经济学评价标准指南》提取纳入文献的相关信息,采用《卫生经济学评价报告标准共识2022年》(Consolidated Health Economic Evaluation Reporting Standards,CHEERS2022)评价纳入文献带状疱疹疫苗接种药物经济学研究质量,对研究角度、模型结构、参数选择、评价结果和敏感性分析等进行描述性分析和定性系统评价。结果共纳入43篇带状疱疹疫苗接种药物经济学研究英文文献,发表时间为2001年4月—2022年6月,其中3篇文献的研究对象为中国人群。23篇文献的研究质量分数>80%(为高质量),20篇分数为65%~80%(为中高质量)。39篇文献带状疱疹疫苗接种药物经济学研究采用成本–效用分析(cost-utility analysis,CUA)评价方法;31篇文献从全社会角度对带状疱疹疫苗接种药物经济学研究进行了评价。42篇文献的研究结果显示,具有正常免疫功能的人群接种带状疱疹疫苗具有经济效益,接种年龄、阈值、疫苗成本、接种方案对结果具有显著影响。在纳入的3篇研究对象为中国人群的文献中,2篇研究结果显示接种带状疱疹疫苗具有经济效益;1篇显示60~70岁老年人接种带状疱疹疫苗最具有经济效益。结论建议基于我国本土数据,开展高质量带状疱疹疫苗接种的药物经济学研究,为该疫苗的免疫接种和HZ的预防提供依据。
Objective To systematically evaluate the pharmacoeconomic research on herpes zoster(HZ)vaccine administration,providing reference for related research and prevention of HZ.Methods Based on the theme words such as'herpes zoster','herpes zoster vaccines','pharmacoeconomics','cost-effectiveness analysis',the literature of pharmacoeconomic study on herpes zoster vaccination was retrieved from 4 Chinese databases and 4 English databases from our library to January 2023.Two researchers independently screened the retrieved literature twice.Relevant information of the included literature was extracted according to the Guidelines for Conducting Economic Evaluation of Immunization Programs of the World Health Organization.The quality of pharmacoeconomic studies on herpes zoster vaccination in the included literature was evaluated using the Consolidated Health Economic Evaluation Reporting Standards(CHEERS2022).Descriptive analysis and qualitative systematic evaluation were conducted on research perspectives,model structures,parameter selection,evaluation results,and sensitivity analyses.Results A total of 43English literature on the economic study of herpes zoster vaccine vaccination drugs were included,published from April 2001 to June 2022,among which 3 articles focused on the Chinese population.The research quality scores of 23 articles were>80%(high quality),and 20 articles scored between 65%and 80%(mid-high quality).Among the 39 articles,the economic study of herpes zoster vaccine vaccination drugs was evaluated using cost-utility analysis(CUA);31 articles evaluated the economic study of herpes zoster vaccine vaccination drugs from a societal perspective.The results of42 articles showed that immunocompetent individuals who received herpes zoster vaccine had economic benefits,and the age of vaccination,threshold,vaccine cost,and vaccination scheme had significant effects on the results.Among the 3 articles focusing on the Chinese population,2 articles showed that vaccination with herpes zoster vaccine was economically beneficial,and 1 article showed that the elderly aged 60 to 70 years had the most economic benefits from herpes zoster vaccine vaccination.Conclusion The economic study of vaccination with high-quality herpes zoster vaccine based on domestic data in China is recommended to provide evidence for immunization and prevention of HZ.
作者
刘欣平
杨子祎
李馨雨
常玉兰
田磊
LIU Xinping;YANG Ziyi;LI Xinyu;CHANG Yulan;TIAN Lei(International Pharmaceutical Business School,China Pharmaceutical University,Nanjing 211198,China;Center for Pharmaceutical Economic Evaluation,China Pharmaceutical University,Nanjing 211198,China)
出处
《中国公共卫生》
CAS
CSCD
北大核心
2024年第2期152-162,共11页
Chinese Journal of Public Health
关键词
带状疱疹疫苗
药物经济学
系统评价
herpes zoster vaccine
pharmacoeconomics
systematic evaluation
